Artemis Medicare Services Limited has notified the stock exchanges of an amendment to its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI), pursuant to Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The amended Code was approved by the Board of Directors on May 8, 2026, and has been uploaded on the company's website at www.artemishospitals.com/investors . The intimation was submitted by Poonam Makkar, Company Secretary and Compliance Officer.

Code Overview and Effective Dates

The Code was originally adopted at a Board meeting and has since been periodically reviewed and updated. The key dates associated with the Code are as follows:

Objective and Scope

The Code is designed to ensure timely and adequate disclosure of UPSI that may impact the price of the company's securities, while maintaining uniformity, transparency, and fairness in dealings with all stakeholders. It also aims to preserve the confidentiality of UPSI and prevent its misuse. The Code applies to all persons within the organisation who may come into possession of price-sensitive information.

Key Norms for Fair Disclosure

The amended Code sets out a comprehensive framework of norms governing the handling and dissemination of UPSI. The principal requirements include:

• Prompt public disclosure of UPSI that would impact price discovery, as soon as credible and concrete information comes into being
• Uniform and universal dissemination of UPSI to all Stock Exchanges and on the company's official website to avoid selective disclosure
• Restricted external communication, with only designated Authorised Spokespersons permitted to discuss company matters with media, investors, and the investment community
• Prompt remediation in cases where UPSI is disclosed selectively or inadvertently, through immediate dissemination to Stock Exchanges and the company's website
• Fair and appropriate responses to queries on news reports and requests for verification of market rumours from regulatory authorities
• Need-to-know basis handling of all UPSI within the organisation

Authorised Spokespersons

Unless otherwise approved by the Managing Director, only individuals in the following designated positions are authorised to communicate company matters externally:

• Chairman
• Managing Director
• Chief Financial Officer
• Chief Business Officer
• Head – Investor Relations, M&A and Organization Growth Strategy
• Chief People Officer

Analyst Interactions and Record-Keeping

The Code specifies that the company shall provide only public information to analysts, research personnel, investor groups, and institutional investors. At least two Authorised Representatives are required to be present at all meetings and conference calls with analysts to prevent misquoting or misrepresentation. Transcripts and recordings of such meetings are to be uploaded on the company's website in accordance with applicable laws.

Confidentiality Safeguards and Legitimate Purpose Policy

Persons privy to UPSI are required to adopt specific safeguards to preserve confidentiality, including maintaining secure physical files, password-protected computer access, and deletion or destruction of confidential files after use. The Code also incorporates a Policy for Determination of Legitimate Purpose, framed under Regulation 3(2A) of the SEBI Insider Trading Regulations. This policy outlines factors to assess whether sharing of UPSI in a given instance constitutes a legitimate purpose, including whether the sharing is in the ordinary course of business, in the best interests of the company, or required to fulfil legal or contractual obligations. A structured digital database is to be maintained internally—with time stamping and audit trails—recording the nature of UPSI shared and the identities of persons involved, including their Permanent Account Numbers or other authorised identifiers.

Artemis Medicare Services Limited has submitted its Monitoring Agency Report for the quarter ended March 31, 2026 (Q4FY26), pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 162A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The report, prepared by CARE Ratings Limited in its capacity as Monitoring Agency, pertains to the utilization of proceeds from the company's Preferential Issue of Compulsorily Convertible Debentures aggregating to Rs. 330.00 crore. The Audit Committee reviewed the report at its meeting held on May 8, 2026.

Issue and Issuer Details

The Preferential Issue was undertaken by Artemis Medicare Services Limited, a company operating in the Healthcare Services – Hospital sector. The promoters are Mr. Onkar Kanwar and Constructive Finance Private Limited. The key details of the issue are summarized below:

Utilization of Issue Proceeds

During Q4FY26, the company utilized Rs. 74.62 crore towards supporting acquisition, expansion, and capital expenditure requirements. Specifically, the company signed a Medical Service Agreement (MSA) with Dr Vidyasagar Kaushalya Devi Memorial Health Centre and paid an additional advance revenue share of Rs. 74.62 crore as per the terms of the MSA. No amount was utilized towards General Corporate Purposes during the quarter. The following table captures the progress in utilization of the issue proceeds:

Deployment of Unutilized Proceeds

The total unutilized amount of Rs. 193.11 crore as at the end of the quarter has been deployed across fixed deposits with multiple banks. The company also received interest of Rs. 0.05 crore on matured Fixed Deposits, which has been reinvested in Fixed Deposits. The details of the deployment are as follows:

Compliance and Deviation Status

The Monitoring Agency confirmed that all utilization is in accordance with the disclosures in the Offer Document, with no deviations observed from earlier monitoring agency reports. The means of finance for the disclosed objects have not changed. No favorable or unfavorable events affecting the viability of the objects were reported, and no other material information affecting investor decision-making was identified. Both objects of the issue — acquisition, expansion, and capital expenditure requirements, as well as General Corporate Purposes — are listed as ongoing, with a completion date of May 15, 2026 as per the Offer Document, and no delay in days or months has been reported.

The Chartered Accountant's certificate relied upon for this report was issued by M/s T R Chadha & Co. LLP, Statutory Auditors of Artemis Medicare Services Limited, dated April 30, 2026. The report notes that the CA certificate provides limited assurance, and the procedures performed are less in extent than those for a reasonable assurance engagement.